

August 08, 2024

The Manager
BSE Limited (SME),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Dear Sir,

Scrip No. 543363
BSE Symbol: PREVEST

Sub: **Outcome of the Board Meeting held today i.e., August 08, 2024**

With reference to the captioned subject and in compliance with the regulation 30 and 33 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, August 08, 2024 (commenced at 03:30 p.m. and concluded at 04.35 p.m.), inter-alia has the following:

1. Considered and approved the un-audited (Standalone and consolidated) financial results of the Company for the quarter ended on June 30, 2024.
2. Considered and approved the Limited Review Report of the Auditors, in respect of the un-audited (Standalone and consolidated) financial results of the Company for the quarter ended on June 30, 2024.
3. Considered and approved the Directors' Report along with Management Discussion and Analysis Report for the financial year ended March 31, 2024.
4. Considered and decided to hold the 25th Annual General Meeting of the Members of the Company on Friday, September 06, 2024.
5. Considered and appointed VNB and Company, Chartered Accountants as an internal Auditor of the Company for the financial year 2024-25.
6. Considered and appointed NKM and Associates, Company Secretaries as a Secretarial Auditor of the Company for the financial year 2024-2025.
7. Recommendation of payment of Final Dividend on Equity Shares at the rate of 10% (Ten per cent) [i.e., 1.00/- (Rupees One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] for the Financial Year ended March 31, 2024, subject to approval of shareholders at the ensuing Annual General Meeting. The dividend, if approved, shall be paid within the prescribed timeline.

A copy of the un-audited (Standalone and consolidated) Financial Results adopted and approved by the Board of Directors for the quarter ended on June 30, 2024, and limited review report of the Auditors thereon is attached herewith for your perusal.

Please take the same on your records and suitably disseminated at all concerned.

Thanking You,
Yours faithfully,

For Prevest Denpro Limited

Aman Sadhotra
Company Secretary and Compliance officer
Membership No- 66562

Independent Auditor's Limited Review Report on Unaudited Standalone Quarter Ended financial results of PREVEST DENPRO LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Prevest Denpro Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Prevest Denpro Limited** ("the Company"), for the Quarter ended 30th June, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 25, (AS 25) "Interim Financial Reporting" prescribed under section 133 of the companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles and generally accepted in India, read with the circular is the responsibility of the company's management and has been approved by the Board of Director of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable Accounting Standards (AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates
Chartered Accountants
FRN: 106456W

HEMANT
RADHAKISHAN
AN BOHRA

Digitally signed by
HEMANT
RADHAKISHAN
BOHRA
Date: 2024.08.08
15:53:51 +05'30'

Hemant Bohra
Partner
M. NO.: 165667
UDIN: 24165667BKEZGL9116
Place: Mumbai
Date: 8th August 2024

Statement of Standalone Financials Results for the Quarter ended on 30th June 2024

Rs In Lakh

	PARTICULARS	Quarter Ended		Year Ended	
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		Unaudited	Audited	Unaudited	Audited
1	Income From Operation				
	(a) Net Sales / Income from Operation (Net of Taxes)	1,334.24	1,624.49	1,339.40	5,643.98
	(b) Other Income	86.42	83.98	60.52	286.16
	Total Revenue	1,420.66	1,708.46	1,399.92	5,930.14
2	Expenses				
	(a) Cost of Material Consumed	290.48	407.28	352.84	1,417.33
	(b) Purchase of Stock-in- Trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(9.24)	-0.58	(9.21)	(17.99)
	(d) Finance Cost	-	-	-	-
	(d) Employee benefit expenses	248.94	244.11	239.60	953.99
	(e) Depreciation and amortization expenses	47.69	46.14	17.49	127.63
	(f) Other Expenses	355.32	385.46	259.57	1,307.72
	Total Expenses	933.20	1,082.41	860.30	3,788.69
3	Profit/(Loss) from before exceptional and extraordinary items (1-2)	487.46	626.05	539.62	2,141.46
	Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)	487.46	626.05	539.62	2,141.46
	Financial Cost				
	Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)	487.46	626.05	539.62	2,141.46
4	Exceptional Item				
5	Profit/(Loss) from ordinary activities before tax (3+4)	487.46	626.05	539.62	2,141.46
6	Tax Expenses				
	Current Tax	112.77	143.02	135.39	497.52
	Earliyer Year Tax	-	-	-	-
	Deffered Tax	9.54	16.69	-4.22	31.57
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	365.14	466.35	408.45	1,612.37
8	Extraordinary Item (net of tax Rs expenses)				
9	Net profit/(loss) for the period (7+8)	365.14	466.35	408.45	1,612.37
	Details of Share Capital				
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.				7,660.12
12	Earnings per Share (EPS) , in Rs (not annualised) (Equity Share of face value of Rs 10/- each)				
	(a) Basic	3.04	3.89	3.40	13.44
	(b) Diluted	3.04	3.89	3.40	13.44

Notes:-

- The above financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Thursday, 8th August 2024.
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India
- The figures for the previous period have been restated / regrouped / reclassified, wherever necessary, in order to make them comparable.


Atul Modi
 (Managing Director)
 DIN-00788272



Independent Auditor's Limited Review Report on Consolidated Unaudited Quarter Ended financial results of PREVEST DENPRO LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Prevest Denpro Limited,

We have reviewed the accompanying statement of unaudited Consolidated financial results ('the Statement') of **Prevest Denpro Limited** ('the Holding Company'), its Subsidiary (together referred to as "the Group") for the Quarter ended 30th June, 2024 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, (AS 25) "Interim Financial Reporting" prescribed under section 133 of the companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles and generally accepted in India, read with the circular is the responsibility of the Holding company's management and has been approved by the Board of Director of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

This statement Includes the results of the following entity: -

- I. Densio Biomed Limited

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards (AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates
Chartered Accountants
FRN: 106456W

HEMANT
RADHAKISHAN
AN BOHRA

Digitally signed by
HEMANT
RADHAKISHAN
BOHRA
Date: 2024.08.08
15:53:13 +05'30'

Hemant Bohra

Partner

M. NO .: 165667

UDIN: 24165667BKEZGM2974

Place: Mumbai

Date: 8th August 2024

Statement of Consolidated Financials Results for the Quarter ended on 30th June 2024

Rs. In Lakhs

	PARTICULARS	Quarter Ended		Quarter Ended	Year Ended
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		Unaudited	Audited	Unaudited	Audited
1	Income From Operation				
	(a) Net Sales / Income from Operation (Net of Taxes)	1,335.56	1,623.51	1,339.40	5,642.89
	(b) Other Income	86.43	83.98	60.52	286.17
	Total Revenue	1,421.99	1,707.50	1,399.92	5,929.05
2	Expenses				
	(a) Cost of Material Consumed	290.48	365.53	352.84	1,375.58
	(b) Purchase of Stock-in- Trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	(9.29)	-2.39	(9.21)	(19.99)
	(d) Finance Cost	-	-	-	-
	(d) Employee benefit expenses	268.29	257.11	239.60	987.81
	(e) Depreciation and amortization expenses	47.69	46.14	17.49	127.63
	(f) Other Expenses	334.50	403.64	259.57	1,314.80
	Total Expenses	931.68	1,070.03	860.30	3,785.83
3	Profit/(Loss) from before exceptional and extraordinary items (1-2)	490.31	637.47	539.62	2,143.22
4	Exceptional Item				
5	Profit/(Loss) from ordinary activities before tax (3+4)	490.31	637.47	539.62	2,143.22
6	Tax Expenses				
	Current Tax	113.49	143.46	135.39	497.96
	Deferred Tax	9.54	16.69	-4.22	31.57
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	367.27	477.32	408.45	1,613.69
8	Extraordinary Item (net of tax Rs expenses)				
9	Net profit/(loss) for the period (7+8)	367.27	477.32	408.45	1,613.69
10	Details of Share Capital				
	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year.				7661.44
12	Earnings per Share (EPS) , in Rs (not annualised) (Equity Share of face value of Rs 10/- each)				
	(a) Basic	3.06	3.98	3.40	13.45
	(b) Diluted	3.06	3.98	3.40	13.45

Notes:-

- The above Consolidated financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Thursday, 8th August 2024.
- This consolidated financial result includes, results of Denvisio Biomed Limited (Wholly Owned Subsidiary of Prevest Denpro Limited)
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Consolidated Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India



Atul Modi
 (Managing Director)
 DIN-00788272